AI assistant
Moderna, Inc. — Director's Dealing 2024
Sep 10, 2024
30610_dirs_2024-09-10_2b15d77d-c0b5-4b13-b059-d7e59249d664.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-09-06
Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-06 | Common Stock | M | 1139 | — | Acquired | 18705 | Direct |
| 2024-09-09 | Common Stock | S | 551 | $73.5731 | Disposed | 18154 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-06 | Restricted Stock Units | $ | M | 1139 | Disposed | Common Stock (1139) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive
plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.